Dutch DNA labelling firm Kreatech raises funds
This article was originally published in Clinica
Executive Summary
Kreatech Biotechnology of Amsterdam, the Netherlands, has raised E6m ($6.5m) in a third round of equity funding led by 3i and including Life Science Partners of the Netherlands and Germany, and Alafi Capital of the US. Kreatech's specialism is the labelling of nucleic acid and proteins. It intends to direct the funds towards its development programmes, as well as setting up US sales and support operations.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.